3 stories
Neglected no more
Biogen backs $17 million round for Ataxion, gets option to acquire the startup
Joshua Resnick is co-founder and chief executive at Ataxion (Photo courtesy of Atlas Venture)
Biogen Idec Inc. is targeting a yet-untreated disease that affects 150,000 Americans while seeking to expand its business of producing drugs for neurological disorders through a deal with a young Cambridge startup. Cambridge-based Biogen today said it has backed Ataxion, a startup founded a year ago by Cambridge venture capital firm Atlas Venture. Both Biogen and Atlas took part in a $17 million funding deal for the startup, which could also see Ataxion acquired by Biogen if certain milestones are achieved. Read More